FDA approves Barhemsys, new option for postop nausea and vom
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
The US Food and Drug Administration (FDA) has approved amisulpride injection (Barhemsys, Acacia Pharma) for the prevention and treatment of postoperative nausea and vomiting (PONV) in adults.

Amisulpride injection is the first and only antiemetic to be approved for the rescue treatment of PONV in patients who have failed prior prophylaxis using the current standard of care. For the prevention of PONV, amisulpride can be used either alone or in combination with an antiemetic of a different class.

An estimated 16 million surgical patients each year in the US suffer from PONV despite receiving prophylaxis.

In four phase 3 trials involving surgical patients and healthy volunteers, amisulpride injection demonstrated significant benefits in the treatment and prevention of PONV," Gabriel Fox, Acacia Pharma's chief medical officer, said in a news release announcing the approval.

In one randomized, double-blind, placebo-controlled study involving 465 patients who had failed the most commonly used antiemetic prophylaxis, a single 10 mg dose of amisulpride injection was significantly more effective than placebo at treating patients (42% vs 29%; P = .003).

"It is often considered by patients to be the most undesirable complication of surgery, even worse than pain. It is therefore very welcome to be able to add Barhemsys to the treatment arsenal, especially for rescue treatment of patients failing standard prophylaxis, where we previously had no approved agent," said TJ Gan, MD, chairman of the Department of Anesthesiology at Stony Brook University in New York.

The company expects to launch amisulpride injection in the second half of this year.

Source: https://www.medscape.com/viewarticle/925864
J●y P●●●●r and 1 others like this
Like
Comment
Share